Trial intelligence / Profile preview

Phase III first-line study of pemigatinib versus gemcitabine + cisplatin in FGFR2-rearranged unresectable or metastatic cholangiocarcinoma

CTR20201757Phase 3Completed

Sponsor

Incyte

Start

May 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1